OncoTherapy Science (TSE:4564) Shares Outstanding (EOP): 383.6 Mil (As of Mar. 2026)


TSE:4564 OncoTherapy Science Inc TSE:4564
50 GF Score
Price 円21.00
GF Value 円17.04
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science Shares Outstanding (EOP)?

OncoTherapy Science TSE:4564 +5.00% 50 Shares Outstanding (EOP) is 383.6 Mil as of Mar. 2026. GuruFocus rates TSE:4564 with a GF Score™ of 50/100 and a GF Value™ of 円17.04 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. OncoTherapy Science's shares outstanding for the quarter that ended in Mar. 2026 was 383.6 Mil.

OncoTherapy Science's quarterly shares outstanding increased from Sep. 2025 (338.6 Mil) to Mar. 2026 (383.6 Mil). It means OncoTherapy Science issued new shares from Sep. 2025 to Mar. 2026 .

OncoTherapy Science's annual shares outstanding increased from Mar. 2025 (271.6 Mil) to Mar. 2026 (383.6 Mil). It means OncoTherapy Science issued new shares from Mar. 2025 to Mar. 2026 .


OncoTherapy Science  (TSE:4564) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


OncoTherapy Science Shares Outstanding (EOP) Related Terms


OncoTherapy Science Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science Shares Outstanding (EOP) Chart

OncoTherapy Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 192.64 192.64 217.64 271.64 383.64

OncoTherapy Science Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 217.64 271.64 271.64 338.64 383.64

TSE:4564 vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, OncoTherapy Science's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoTherapy Science Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where OncoTherapy Science's Shares Outstanding (EOP) falls into.


TSE:4564
50GF Score
OncoTherapy Science Inc TSE:4564
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoTherapy Science Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 383.6 Mil mean?
OncoTherapy Science (TSE:4564) has a Shares Outstanding (EOP) of 383.6 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on OncoTherapy Science and its competitors.
Is OncoTherapy Science's Shares Outstanding (EOP) too high?
OncoTherapy Science's current Shares Outstanding (EOP) is 383.6 Mil. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Shares Outstanding (EOP) compare to VRTX and REGN?
OncoTherapy Science's Shares Outstanding (EOP) of 383.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current Shares Outstanding (EOP) is 383.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円17.04, compared to a current price of 円21.00 — trading 23.2% above its estimated fair value. The current Shares Outstanding (EOP) is 383.6 Mil. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current Shares Outstanding (EOP) is 383.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoTherapy Science (TSE:4564) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of 円21.00 is trading 23.2% above its estimated GF Value™ of 円17.04. GuruFocus considers OncoTherapy Science to be Modestly Overvalued.

Key valuation signals for TSE:4564:

  • Shares Outstanding (EOP): 383.6 Mil
  • GF Value™: 円17.04 vs. price of 円21.00 (23.2% above fair value)
  • GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OncoTherapy Science Business Description

Other Exchanges 30O:Germany
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score

Get the complete analysis for TSE:4564

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円21.00
Price
円17.04
GF Value